
David S. Tierney is currently President & CEO of Aramis Biosciences, a clinical-stage biopharmaceutical company, spun out of Harvard’s Mass Eye and Ear, that is developing a first-in-class topical interleukin-17A antagonist for the treatment of Dry Eye Disease. David is an experienced entrepreneurial healthcare executive with a strong track record of success in the pharmaceutical and medical device arena. He has extensive experience in research and development especially taking products through the FDA and EMEA approval processes. He has successfully built specialty commercial organizations and launching products in the United States and Europe.
David has twice been recognized as a New Jersey Ernst and Young Entrepreneur of the Year for Valera Pharmaceuticals (2005) and Oceana Therapeutics (2011). David received his medical degree from the Royal College of Surgeons in Ireland in 1987.